1-20 of 96
Philipp Le Coutre
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial

Open Access
Clinical Trials & Observations
Jorge E. Cortes, Timothy P Hughes, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiri Mayer, Yoew-Tee Goh, Philipp le Coutre, Gabriel Etienne, Inho Kim, David Andorsky, Felice Bombaci, Ghayas C. Issa, Naoto Takahashi, Shruti Kapoor, Rajendra Jinwal, Kamel Malek, Tracey McCulloch, Lillian Yau, Richard A Larson, Andreas Hochhaus
Journal: Blood
Blood blood.2025029210.
https://doi.org/10.1182/blood.2025029210
Published: 2025
Includes: Supplemental data
Journal Articles

Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study

Free
Susan Branford, Jorge Cortes, Naoto Takahashi, Richard Larson, Ghayas Issa, Felice Bombaci, Jianxiang Wang, Dong-Wook Kim, Dennis Kim, Jiri Mayer, Yeow Tee Goh, Philipp le Coutre, Inho Kim, Gabriel Etienne, Shruti Kapoor, Rajendra Jinwal, Kamel Malek, Amila Sarac, Andreas Bruederle, Pablo Serrano-Fernandez, Pedro Milanez-Almeida, Andreas Hochhaus, Timothy Hughes
Journal: Blood
Blood (2025) 146 (Supplement 1): 73.
https://doi.org/10.1182/blood-2025-73
Published: 2025
Journal Articles

A phase II Study of fedratinib and nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment – fraction Study / IKF051 / gsg-MPN-006

Free
Susanne Isfort, Nikolas Von Bubnoff, Haifa Kathrin Al-Ali, Heiko Becker, Frank Stegelmann, Thorsten Götze, Philipp le Coutre, Martin Griesshammer, Adrian Schwarzer, Luisa Wohn, Salah-Eddin Al-Batran, Johanna Riedel, Francesca Palandri, Kirsi Manz, Andreas Hochhaus, Konstanze Döhner, Florian Heidel
Journal: Blood
Blood (2025) 146 (Supplement 1): 5589.
https://doi.org/10.1182/blood-2025-5589
Published: 2025
Journal Articles

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

Free
Jorge Cortes, Andreas Hochhaus, Kathryn Flynn, Felice Bombaci, Ghayas Issa, Richard Larson, Jianxiang Wang, Dong-Wook Kim, Dennis Kim, Jiri Mayer, Yeow Tee Goh, Philipp le Coutre, Inho Kim, Gabriel Etienne, Shruti Kapoor, Rajendra Jinwal, Kamel Malek, Lillian Yau, Timothy Hughes, Naoto Takahashi
Journal: Blood
Blood (2025) 146 (Supplement 1): 1997.
https://doi.org/10.1182/blood-2025-1997
Published: 2025
Journal Articles

ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors

Free
Massimo Breccia, Andreas Hochhaus, Philipp le Coutre, Dragana Milojkovic, Dennis Kim, Soo Min Lim, Carolina Pavlovsky, Thanh Nguyen, Franck Nicolini, Elena Moiraghi, Sebastian Grosicki, Chi Dung Phu, Gabriel Etienne, Fernando Marco De Lucas, Rosa Ayala Diaz, Roberto Abi Rached, Soyoun Park, Peter Schuld, Virginia Pilipovic, Aswin IC, Franz Alisch, Carla Maria Boquimpani, Charles Chuah
Journal: Blood
Blood (2025) 146 (Supplement 1): 1993.
https://doi.org/10.1182/blood-2025-1993
Published: 2025
Journal Articles

Improved long-term tolerability and efficacy of asciminib-based combination therapies in newly diagnosed CML patients - the fascination trial.

Free
Thomas Ernst, Philipp le Coutre, Martina Crysandt, Georg-Nikolaus Franke, Thomas Illmer, Andreas Burchert, Fabian Lang, Susanne Saussele, Lino Teichmann, Markus Radsak, Frank Stegelmann, Joachim Goethert, Stefan Krause, Jenny Rinke, Christian Fabisch, Thomas Lang, Markus Pfirrmann, Andreas Hochhaus
Journal: Blood
Blood (2025) 146 (Supplement 1): 903.
https://doi.org/10.1182/blood-2025-903
Published: 2025
Journal Articles

CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML

Free
Elias Jabbour, Timothy Hughes, Richard Van Etten, David Andorsky, Gonzalo Carreño, Philipp le Coutre, Omer Jamy, Pilar Giraldo, Dong-Wook Kim, Vivian Oehler, Andreas Hochhaus, Jorge Cortes, Michael Mauro, Tonya Marmon, Leanne Holes, Emil Kuriakose, Hagop Kantarjian, Delphine Rea
Journal: Blood
Blood (2025) 146 (Supplement 1): 901.
https://doi.org/10.1182/blood-2025-901
Published: 2025
Journal Articles

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Free
Timothy Hughes, Jorge Cortes, Jennifer Vaughn, Kathryn Flynn, Naoto Takahashi, Ghayas Issa, Felice Bombaci, Jianxiang Wang, Dong-Wook Kim, Dennis Kim, Jiri Mayer, Yeow Tee Goh, Philipp le Coutre, Inho Kim, Gabriel Etienne, Rajendra Jinwal, Andrea Damon, David Wei, Gabriel Marquez, Ennan Gu, Gopi Madhav Bommidi, Andreas Hochhaus, Richard Larson
Journal: Blood
Blood (2025) 146 (Supplement 1): 5549.
https://doi.org/10.1182/blood-2025-5549
Published: 2025
Journal Articles

Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study

Free
Andreas Hochhaus, Philipp le Coutre, Dragana Milojkovic, Dennis Dong Hwan Kim, Soo Min Lim, Carolina Pavlovsky, Thanh HA Nguyen, Franck E. Nicolini, Beatriz Moiraghi, Sebastian Grosicki, Chi Dung Phu, Gabriel Etienne, Fernando Marco De Lucas, Rosa Ayala, Massimo Breccia, Charles Chuah, Giora Sharf, Roberto Abi Rached, Himanshu Pokhriyal, Santoshkumar Tota, Asmae Mirkou, Peter Schuld, Carla Boquimpani
Journal: Blood
Blood (2024) 144 (Supplement 1): 4526.
https://doi.org/10.1182/blood-2024-200017
Published: 2024
Journal Articles

The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients

Free
Thomas Ernst, Jenny Rinke, Philipp le Coutre, Martina Crysandt, Tim H. H. Brummendorf, Andreas Burchert, Fabian Lang, Susanne Saussele, Markus Pfirrmann, Thomas Lang, Christian Fabisch, Andreas Hochhaus
Journal: Blood
Blood (2024) 144 (Supplement 1): 1774.
https://doi.org/10.1182/blood-2024-193991
Published: 2024
Journal Articles

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Free
Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiri Mayer, Yeow Tee Goh, Philipp le Coutre, Gabriel Etienne, Naoto Takahashi, Inho Kim, David Andorsky, Ghayas C. Issa, Felice Bombaci, Shruti Kapoor, Rajendra Jinwal, Lillian Yau, Richard Larson
Journal: Blood
Blood (2024) 144 (Supplement 1): 475.
https://doi.org/10.1182/blood-2024-203757
Published: 2024
Journal Articles

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Free
Jorge E. Cortes, Delphine Rea, Michael J. Mauro, Andreas Hochhaus, Dong-Wook Kim, Koji Sasaki, Fabian Lang, Michael C. Heinrich, Massimo Breccia, Michael W. Deininger, Yeow Tee Goh, Jeroen J.W.M. Janssen, Moshe Talpaz, Valle Gomez G De Soria, Philipp le Coutre, Francois-Xavier Mahon, Daniel Deangelo, Shruti Kapoor, Gessami Sanchez-Olle, Meng Cao, Nithya Agrawal, Timothy P Hughes
Journal: Blood
Blood (2024) 144 (Supplement 1): 1765.
https://doi.org/10.1182/blood-2024-209537
Published: 2024
Journal Articles

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study

Free
Andreas Hochhaus, Dong-Wook Kim, Jorge Cortes, Koji Sasaki, Michael Mauro, Timothy P Hughes, Massimo Breccia, Moshe Talpaz, Hironobu Minami, Yeow Tee Goh, Daniel J. DeAngelo, Fabian Lang, Michael C. Heinrich, Valle Gomez G De Soria, Philipp le Coutre, Gessami Sanchez-Olle, Jomy Jose, Nathalie Pognan, Shruti Kapoor, Delphine Rea
Journal: Blood
Blood (2023) 142 (Supplement 1): 450.
https://doi.org/10.1182/blood-2023-187322
Published: 2023
Journal Articles

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Free
Andreas Hochhaus, Andreas Burchert, Susanne Saussele, Gabriela M Baerlocher, Jiří Mayer, Tim H. Brümmendorf, Paul La Rosée, Dominik Heim, Stefan W. Krause, Philipp le Coutre, Jenny Rinke, Thoralf Lange, Alice Fabarius, Marcel Lorch, Mathias Hanel, Frank Stegelmann, Georg-Nikolaus Franke, Markus P. Radsak, Volker Kunzmann, Daniela Zackova, Danny Himsel, Denise Kohn, Thomas Lang, Rüdiger Hehlmann, Christian Fabisch, Thomas Ernst, Markus Pfirrmann
Journal: Blood
Blood (2023) 142 (Supplement 1): 446.
https://doi.org/10.1182/blood-2023-182792
Published: 2023
Journal Articles

Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph+ CML-CP/AP): Final Results from the Asciminib Phase 1 Study

Free
Jorge Cortes, Fabian Lang, Delphine Rea, Andreas Hochhaus, Massimo Breccia, Yeow Tee Goh, Michael C. Heinrich, Timothy P Hughes, Jeroen J.W.M. Janssen, Philipp le Coutre, Hironobu Minami, Koji Sasaki, Daniel J. DeAngelo, Gessami Sanchez-Olle, Nathalie Pognan, Jomy Jose, Matthias Hoch, Michael Mauro
Journal: Blood
Blood (2023) 142 (Supplement 1): 868.
https://doi.org/10.1182/blood-2023-189270
Published: 2023
Journal Articles

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Free
Katharina Kohlbrenner, Norbert Galuschek, Alice Fabarius, Marcel Reiser, Klaus Fenchel, Eva Esseling, Thomas Göhler, Ralf-Bodo Kühn, Reinhard Depenbusch, Ivo Talah Azeh, Erik Engel, Richard Hansen, Mathias Hanel, Paul Jehner, Maisun Abu-Samra, Markus Ritter, Norbert Gattermann, Henning Pelz, Stefan Fuxius, Burkhard Oswald, Gabriela M Baerlocher, Tim H. Brümmendorf, Dominik Heim, Philipp le Coutre, Andreas Burchert, Dietger Niederwieser, Hans Tesch, Wolf-Karsten Hofmann, Andreas Hochhaus, Rüdiger Hehlmann, Susanne Saussele
Journal: Blood
Blood (2023) 142 (Supplement 1): 4539.
https://doi.org/10.1182/blood-2023-180730
Published: 2023
Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Free
Michael Mauro, Yosuke Minami, Andreas Hochhaus, Elza Lomaia, Sergei Voloshin, Anna Turkina, Dong-Wook Kim, Jane F Apperley, Jorge Cortes, Andre N.R. Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín García Gutiérrez, Koji Sasaki, Carla Maria Boquimpani De Moura Freitas, Shruti Kapoor, Noemi Espurz, Vishal Dhamal, Delphine Rea
Journal: Blood
Blood (2023) 142 (Supplement 1): 4536.
https://doi.org/10.1182/blood-2023-186854
Published: 2023
Journal Articles

Second-Line Ponatinib in Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients Failing or Intolerant to First-Line Second Generation Tyrosine Kinase Inhibitor (TKI) Treatment: An Interim Analysis of the Prospective PONS Trial

Free
Philipp le Coutre, Joachim R Göthert, Susanne Saussele, Uwe Pelzer, Lars Bullinger, Ahmet Elmaagacli, Christian Jehn, Frank Stegelmann, Andreas Hochhaus, Thomas Ernst, Andreas Burchert
Journal: Blood
Blood (2022) 140 (Supplement 1): 12202–12203.
https://doi.org/10.1182/blood-2022-162281
Published: 2022
Journal Articles

ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase

Free
Thomas Ernst, Lioba Schönfeld, Jenny Rinke, Anna Hinze, Saskia N. Nagel, Vivien Schäfer, Thomas Schenk, Christian Fabisch, Tim H. Brümmendorf, Andreas Burchert, Philipp le Coutre, Stefan W. Krause, Susanne Saussele, Fatemeh Safizadeh, Markus Pfirrmann, Andreas Hochhaus
Journal: Blood
Blood (2022) 140 (Supplement 1): 807–808.
https://doi.org/10.1182/blood-2022-165041
Published: 2022
Journal Articles

Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Free
Katharina Kohlbrenner, Norbert Galuschek, Alice Fabarius, Marcel Reiser, Klaus Fenchel, Eva Eßeling, Thomas Göhler, Thomas Geer, Reinhard Depenbusch, Ivo Talah Azeh, Erik Engel, Richard Hansen, Hans-Walter Lindemann, Jürgen Anhuf, Paul Jehner, Maisun Abu-Samra, Markus Ritter, Norbert Gattermann, Henning Pelz, Stefan Fuxius, Burkhard Oswald, Gabriela M Baerlocher, Tim H.H. Brummendorf, Dominik Heim, Philipp le Coutre, Andreas Burchert, Dietger Niederwieser, Hans Tesch, Wolf-Karsten Hofmann, Andreas Hochhaus, Rüdiger Hehlmann, Susanne Saussele
Journal: Blood
Blood (2022) 140 (Supplement 1): 947–949.
https://doi.org/10.1182/blood-2022-159412
Published: 2022